Zacks Research Upgrades Curis (NASDAQ:CRIS) to Hold

Curis (NASDAQ:CRIS) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

A number of other equities research analysts have also recently issued reports on CRIS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Curis in a report on Monday, August 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $43.00.

Curis Stock Performance

NASDAQ:CRIS opened at $1.16 on Wednesday. Curis has a 52-week low of $1.11 and a 52-week high of $39.00. The company has a market cap of $2.42 million, a P/E ratio of -0.08 and a beta of 3.01. The stock’s 50-day simple moving average is $3.35 and its 200 day simple moving average is $9.20.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. As a group, equities analysts predict that Curis will post -24.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Curis

A number of hedge funds and other institutional investors have recently bought and sold shares of CRIS. Nantahala Capital Management LLC acquired a new stake in shares of Curis in the second quarter valued at approximately $1,033,171,000. Stonepine Capital Management LLC bought a new position in shares of Curis during the 2nd quarter worth approximately $1,729,292,000. Cable Car Capital LP acquired a new position in shares of Curis during the 2nd quarter worth approximately $696,000. BlackRock Inc. acquired a new position in shares of Curis during the 2nd quarter worth approximately $28,000. Finally, XTX Topco Ltd bought a new stake in Curis in the 4th quarter valued at $26,000. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.